Published in Inflamm Bowel Dis on November 28, 2010
Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol (2014) 2.11
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther (2013) 1.69
Crohn's disease complicated by strictures: a systematic review. Gut (2013) 1.46
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol (2015) 1.44
Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol (2013) 1.03
Measuring disease activity in Crohn's disease: what is currently available to the clinician. Clin Exp Gastroenterol (2014) 0.92
MRI in Crohn's disease--current and future clinical applications. Nat Rev Gastroenterol Hepatol (2011) 0.88
Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. Am J Gastroenterol (2015) 0.87
Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient (2013) 0.87
Diagnosis and management of intestinal Behçet's disease. Clin J Gastroenterol (2014) 0.87
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol (2013) 0.85
Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease. Inflamm Bowel Dis (2014) 0.84
Current issues of pediatric inflammatory bowel disease in Korea. Korean J Pediatr (2014) 0.82
The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81
Performance of the Montreal classification for inflammatory bowel diseases. World J Gastroenterol (2014) 0.81
Can fecal calprotectin better stratify Crohn's disease activity index? Ann Gastroenterol (2015) 0.81
Impact of medical therapies on inflammatory bowel disease complication rate. World J Gastroenterol (2012) 0.81
When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Ann Gastroenterol (2015) 0.80
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther (2016) 0.79
Magnetic resonance colonography for fibrosis assessment in rats with chronic colitis. PLoS One (2014) 0.79
Measuring structural damage in Crohn's disease. Gastroenterol Hepatol (N Y) (2013) 0.79
Inflammatory bowel disease imaging: Current practice and future directions. World J Gastroenterol (2016) 0.78
Protocol for a prospective multicentre cohort study to develop and validate two new outcome measures for patients with inflammatory bowel disease. BMJ Open (2013) 0.77
IBD: Mucosal healing--EXTENDing our knowledge in Crohn's disease. Nat Rev Gastroenterol Hepatol (2012) 0.77
Assessment of Disease Activity in Small Bowel Crohn's Disease: Comparison between Endoscopy and Magnetic Resonance Enterography Using MRIA and Modified MRIA Score. Gastroenterol Res Pract (2015) 0.77
Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol (2015) 0.77
Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease. J Crohns Colitis (2016) 0.77
Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis. PLoS One (2016) 0.77
Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol (2016) 0.76
Pediatric Magnetic Resonance Enterography: Focused on Crohn's Disease. Pediatr Gastroenterol Hepatol Nutr (2015) 0.76
Predictors of recurrence of Crohn's disease after ileocolectomy: a review. World J Gastroenterol (2014) 0.76
Ultrasonographic imaging of inflammatory bowel disease in pediatric patients. World J Gastroenterol (2015) 0.76
Taking Crohn's disease personally. Rambam Maimonides Med J (2013) 0.76
Current role of capsule endoscopy in Crohn's disease. World J Gastrointest Endosc (2016) 0.75
Endoscopy-based management decreases the risk of postoperative recurrences in Crohn's disease. World J Gastroenterol (2016) 0.75
Surgery in Pediatric Crohn's Disease: Indications, Timing and Post-Operative Management. Pediatr Gastroenterol Hepatol Nutr (2017) 0.75
Crohn's disease in remission or simply smouldering? Ann Gastroenterol (2015) 0.75
Levels of Faecal Calprotectin and Magnetic Resonance Enterocolonography Correlate with Severity of Small Bowel Crohn's Disease: A Retrospective Cohort Study. Sci Rep (2017) 0.75
Efficacy of Thiopurines in Biologic-Naive Japanese Patients With Crohn's Disease: A Single-Center Experience. Intest Res (2015) 0.75
Select a suitable treatment strategy for Crohn's disease: step-up or top-down. EXCLI J (2014) 0.75
SPECT-computed tomography in rats with TNBS-induced colitis: A first step toward functional imaging. World J Gastroenterol (2017) 0.75
Cephalic duodenopancreatectomy for hyperalgic duodenal Crohn's disease fistulized in the pancreatic gland. Case Rep Gastroenterol (2014) 0.75
Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. Clin Gastroenterol Hepatol (2016) 0.75
Why should we define and target early Crohn's disease? Gastroenterol Hepatol (N Y) (2011) 0.75
A Retrospective Evaluation of the Utility of Capsule Endoscopy and Double-Balloon Endoscopy in Crohn's Disease. Gastroenterol Res Pract (2015) 0.75
Relevance of fecal calprotectin and lactoferrin in the post-operative management of inflammatory bowel diseases. World J Gastrointest Surg (2016) 0.75
Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials. Inflamm Bowel Dis (2016) 0.75
Magnetic Resonance Imaging of the Small Bowel in Crohn's Disease: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol (2016) 0.75
Update on Magnetic Resonance Imaging and Ultrasound Evaluation of Crohn's Disease. Gastroenterol Hepatol (N Y) (2016) 0.75
The Cost of Crohn's Disease: Varied Health Care Expenditure Patterns Across Distinct Disease Trajectories. Inflamm Bowel Dis (2016) 0.75
Early Thiopurines Versus Conventional Step-Care Therapy for Modifying the Disease Course of Early Crohn's Disease: A Tertiary Referral Center Cohort Study. Medicine (Baltimore) (2015) 0.75
Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. BMC Gastroenterol (2016) 0.75
Preventing Collateral Damage in Crohn's Disease: The Lémann Index. J Crohns Colitis (2016) 0.75
SICUS and CEUS imaging in Crohn's disease: an update. J Ultrasound (2017) 0.75
Imaging of the small bowel: Crohn's disease in paediatric patients. World J Radiol (2014) 0.75
Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. BMC Med Imaging (2016) 0.75
Diagnostic accuracy of three different MRI protocols in patients with inflammatory bowel disease. Acta Radiol Open (2015) 0.75
An overview of magnetic resonance enterography for Crohn's disease. Dig Dis Sci (2014) 0.75
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut (2017) 0.75
Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea. Dig Dis Sci (2017) 0.75
Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn's Disease Patients Classified i2 on the Rutgeerts Score. Dig Dis Sci (2016) 0.75
The efficacy of active drainage for preventing postoperative organ/space surgical site infections in patients with Crohn's disease. Surg Today (2017) 0.75
Computed tomography--an increasing source of radiation exposure. N Engl J Med (2007) 41.06
Inflammatory bowel disease. N Engl J Med (2002) 21.17
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology (1976) 15.65
A simple index of Crohn's-disease activity. Lancet (1980) 11.12
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Predictability of the postoperative course of Crohn's disease. Gastroenterology (1990) 5.30
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut (2001) 4.23
Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis (2002) 4.13
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology (1979) 3.94
Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum (1972) 3.43
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum (1985) 2.68
Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut (2009) 2.60
Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology (2008) 2.54
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15
CT features of ulcerative colitis and Crohn's disease. AJR Am J Roentgenol (1996) 1.79
Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. Br J Surg (1999) 1.79
Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis (2010) 1.78
Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum (2006) 1.73
MR enterographic manifestations of small bowel Crohn disease. Radiographics (2010) 1.68
Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology (2006) 1.60
MR imaging evaluation of the activity of Crohn's disease. AJR Am J Roentgenol (2001) 1.60
Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol (2003) 1.55
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54
Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol (1995) 1.53
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
CT imaging of colitis. Radiology (2006) 1.35
Role of US in detection of Crohn disease: meta-analysis. Radiology (2005) 1.29
Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum (1985) 1.20
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis (2009) 1.14
Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology (2006) 1.12
Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis (2007) 1.11
Early Crohn disease: a proposed definition for use in disease-modification trials. Gut (2010) 1.11
Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up. Ann Rheum Dis (2004) 1.08
Ultrasound in Crohn's disease of the small bowel. Eur J Radiol (2000) 1.04
Enteroclysis and spiral CT examination in diagnosis and evaluation of small bowel Crohn's disease. Eur J Radiol (2000) 1.00
MR imaging of the small bowel with a true-FISP sequence after enteroclysis with water solution. Invest Radiol (2000) 0.98
Classification of the sequelae of bowel resection for Crohn's disease. Br J Surg (1994) 0.97
Evaluation of treatment response in active Crohn's disease by low-field magnetic resonance imaging. Abdom Imaging (1999) 0.85
[Value of contrast-enhanced MR enterography in pediatric Crohn's disease: preliminary study]. J Radiol (2005) 0.83
Science to practice: do mural attenuation and thickness at contrast-enhanced CT enterography correlate with endoscopic and histologic findings of inflammation in Crohn disease? Radiology (2006) 0.79
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet (2008) 15.51
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2006) 15.14
Helicobacter pylori infection. N Engl J Med (2002) 14.81
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Managing incidental findings in human subjects research: analysis and recommendations. J Law Med Ethics (2008) 12.10
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Transcriptome and genome sequencing uncovers functional variation in humans. Nature (2013) 8.89
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet (2007) 8.50
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med (2008) 7.79
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol (2012) 7.39
Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature (2007) 7.17
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med (2015) 6.71
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet (2009) 6.21
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 5.94
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet (2002) 5.31
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation (2008) 5.20
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Correlation between genetic and geographic structure in Europe. Curr Biol (2008) 5.02
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
PopGen: population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. Community Genet (2006) 4.72
Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity (2007) 4.70
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology (2003) 4.52
Crohn's disease. Lancet (2012) 4.42
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39